Exagen Inc. (NASDAQ:XGN) major shareholder Hunt Holdings Limited Partners sold 7,394 shares of the business’s stock in a transaction that occurred on Monday, January 11th. The shares were sold at an average price of $16.03, for a total value of $118,525.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Hunt Holdings Limited Partners also recently made the following trade(s):
- On Friday, January 8th, Hunt Holdings Limited Partners sold 15,186 shares of Exagen stock. The shares were sold at an average price of $16.07, for a total value of $244,039.02.
- On Wednesday, November 11th, Hunt Holdings Limited Partners sold 150 shares of Exagen stock. The stock was sold at an average price of $16.00, for a total value of $2,400.00.
- On Monday, November 9th, Hunt Holdings Limited Partners sold 6,752 shares of Exagen stock. The stock was sold at an average price of $16.04, for a total value of $108,302.08.
XGN stock opened at $14.47 on Thursday. Exagen Inc. has a one year low of $10.29 and a one year high of $25.41. The firm has a market cap of $183.07 million and a price-to-earnings ratio of -1.18. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.77 and a current ratio of 12.77. The firm has a 50-day simple moving average of $12.97 and a two-hundred day simple moving average of $13.92.
Exagen (NASDAQ:XGN) last posted its earnings results on Tuesday, November 10th. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.14. The company had revenue of $10.78 million during the quarter, compared to analysts’ expectations of $9.03 million. Exagen had a negative net margin of 39.49% and a negative return on equity of 29.10%. As a group, equities analysts predict that Exagen Inc. will post -1.68 earnings per share for the current fiscal year.
A number of analysts recently weighed in on XGN shares. BTIG Research started coverage on shares of Exagen in a research note on Thursday, October 8th. They issued a “buy” rating and a $18.00 price objective for the company. KeyCorp began coverage on shares of Exagen in a research report on Tuesday, November 10th. They issued an “overweight” rating and a $32.00 price target for the company. William Blair reissued an “outperform” rating on shares of Exagen in a report on Wednesday, November 11th. Finally, Zacks Investment Research lowered Exagen from a “buy” rating to a “hold” rating in a report on Thursday, December 31st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $21.00.
Institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp purchased a new position in Exagen during the 2nd quarter worth $186,000. Goldman Sachs Group Inc. purchased a new stake in Exagen in the second quarter valued at about $2,382,000. American International Group Inc. boosted its holdings in Exagen by 48.9% in the second quarter. American International Group Inc. now owns 2,920 shares of the company’s stock worth $36,000 after acquiring an additional 959 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Exagen during the second quarter worth about $374,000. Finally, Bank of America Corp DE increased its holdings in shares of Exagen by 115.3% during the second quarter. Bank of America Corp DE now owns 2,698 shares of the company’s stock valued at $33,000 after acquiring an additional 1,445 shares in the last quarter. Hedge funds and other institutional investors own 29.21% of the company’s stock.
Exagen Inc develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.